Transfusion Requirements in Gastrointestinal (GI) Bleeding
Recruitment status was: Recruiting
|First Received Date ICMJE||December 21, 2006|
|Last Updated Date||December 28, 2010|
|Start Date ICMJE||October 2002|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE
||Mortality at the 45th day [ Time Frame: 45 days ]|
|Original Primary Outcome Measures ICMJE
||Mortaly at the 30th day|
|Change History||Complete list of historical versions of study NCT00414713 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Transfusion Requirements in Gastrointestinal (GI) Bleeding|
|Official Title ICMJE||Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding.|
Recently it has been suggested that a restrictive transfusion of units of Red Cells (URC) may improve the outcome of ICU patients with anemia. Furthermore, it has been suggested that the transfusion of URC may be deleterious for the hemostatic process of bleeding lesions, which suggest that a restrictive transfusion may be valuable in patients which gastrointestinal bleeding. Transfusion of URC may also increase portal pressure which may be detrimental to control acute portal hypertensive bleeding.
The aim of the present study is to assess whether a restrictive transfusions may improve the outcome of patients with acute nonvariceal gastrointestinal bleeding, and also whether such a restrictive strategy may improve the outcome of bleeding episodes related with portal hypertension.
The study will be carried out with a prospective, randomized and controlled design comparing the restrictive transfusion strategy with the usual nonrestrictive transfusional strategy. Overall 860 patients will be included; 430 in each group.
The main outcome measure will be survival. All deaths occurred within the 30 days after admission, will be considered. Secondary outcomes will include rebleeding and complications related to treatment, and related to the bleeding episode itself. Portal pressure will be measured to assess the influence of the transfusions strategy on fluctuations of this parameter, and the relationship with the clinical course of bleeding episode.
The study will be performed at the Bleeding Unit of our hospital during a period of 3 years.
At the present time there does not exist established criteria to decide when it is necessary a blood transfusion in a patient with digestive hemorrhage, neither which should be the red cells concentrates (RBC) amount that the most of the patients will need.
In clinical studies made in critical patients undergoing a by-pass coronary surgery, the strategy of restrictive transfusion showed results similar to the one obtained with more liberal strategies, even with an improvement of the survival and a smaller rate of complications related to transfusion.
In animal models of GI bleeding (and also in human studies in the traumatic hemorrhage), precocious or vigorous transfusion made hemostasia more difficult. Also an increase in the rate of rebleeding has been observed, suggesting that arterial hypotension combined with hypovolemia aid hemostasia, stabilize the clot. It leads to diminish by itself the rebleeding rate.
In the same way, in patients with portal hypertension associated hemorrhage, aggressive replacement of volemia causes increases on the portal pressure, and that could lead in a condition of bigger difficulty for the control of the hemorrhage and greater rate of recidiva.
On the other hand, potential complications associated with the transfusion would be seen potentially reduced.
Our randomized prospective study tries to demonstrate that the use of a restrictive strategy in the sanguineous transfusion in patients with acute GI upper bleeding can be at least as beneficial than the habitually used.
Moreover, restricted transfusion in these patients could improve short term survival, as well as a smaller rate transfusion-related or rebleeding.
In portal hypertension related hemorrhage, restricted transfusion could avoid fluctuations of portal pressure caused by transfusion during the acute phase of hemorrhage, which could favor hemostasia in these patients.
The main objective is to evaluate if restrictive transfusion criterion in patients with acute upper GI hemorrhage can maintain the rates of survival obtained using habitual transfusion criteria, or to even improve them.
The more important secondary targets consist in evaluating if these restrictive transfusional parameters are also accompanied by a better control of the hemorrhage, and also to evaluate if this is accompanied by a smaller rate of complications.
Other additional objectives would be:
Ours is a prospective, randomized and controlled study, in which patients with acute upper GI bleeding will be randomized into two groups of transfusional RBC treatment with:
Group 1 (of restricted transfusion), that constitutes the training group: they will receive UCH transfusion when the hemoglobin descends below 70 G/L, to maintain values of hemoglobin of 70 to 90 G/L.
Group 2 (of habitual transfusion), that constitutes the group control: they will receive transfusion according to habitual practice, when the hemoglobin descends below 90 G/L, to maintain values of hemoglobin of 90 to 110 G/L.
Randomization will be made by means of a closed opaque envelope that will contain the treatment option that will have been obtained by means of a listing of random numbers generated by computer.
The patients will be randomized as soon as the inclusion criteria/exclusion has been verified.
Randomization will be stratified according to the origin of the hemorrhage (related to portal hypertension or not).
NUMBER OF PREDICTED SUBJECTS AND JUSTIFICATION:
430 patients in every group will be required (860 altogether), to objective a mortality reduction of 5%, with a global expected mortality secondary to GI bleeding at the control group of 10%, with a type I error of 5% and a type II error of 20%.
280 patients in each group will be required (560 altogether) to objective a difference of 6%, with the detailed parameters.
An expected period of 3 years to include this
|Study Type ICMJE||Interventional|
|Study Phase||Phase 4|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Intervention ICMJE||Procedure: red blood cell transfusion
red blood cell transfusion
|Publications *||Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santaló M, Muñiz E, Guarner C. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21. doi: 10.1056/NEJMoa1211801. Erratum in: N Engl J Med. 2013 Jun 13;368(24):2341.|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Unknown status|
|Estimated Enrollment ICMJE||860|
|Estimated Completion Date||December 2007|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Spain|
|Removed Location Countries|
|NCT Number ICMJE||NCT00414713|
|Other Study ID Numbers ICMJE||EC/02/102/1729 HCSCSP|
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Not Provided|
|Study Sponsor ICMJE||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|
|Collaborators ICMJE||Not Provided|
|PRS Account||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|
|Verification Date||December 2010|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP